Comparison of Chemotherapeutic Regimens Frequently Used in
Metastatic Non-squamous NSCLC Treatment

J 2021

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA et. al.

Basic information

Original name

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

Authors

KREJCI, Daniel (203 Czech Republic), Petr OPALKA (203 Czech Republic), Jana KREJCI (203 Czech Republic), Milada ZEMANOVA (203 Czech Republic), Petra ZEMANOVA (203 Czech Republic), Juraj KULTAN (203 Czech Republic), Ondrej FISCHER (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), Monika BRATOVÁ (203 Czech Republic, belonging to the institution), Marketa CERNOVSKA (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Helena ČOUPKOVÁ (203 Czech Republic, belonging to the institution), Karolína HURDÁLKOVÁ (203 Czech Republic), Magda BAŘINOVÁ (203 Czech Republic), Leona KOUBKOVA (203 Czech Republic), Daniel DOLEZAL (203 Czech Republic), Martin SAFANDA (203 Czech Republic), Milos PESEK (203 Czech Republic) and Martin SVATON (203 Czech Republic)

Edition

Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.435

RIV identification code

RIV/00216224:14110/21:00122867

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/anticanres.15039

UT WoS

000648660800009

Keywords in English

NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed

Abstract

V originále

Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.

Citovat

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Monika BRATOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Helena ČOUPKOVÁ, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ, Leona KOUBKOVA, Daniel DOLEZAL, Martin SAFANDA, Milos PESEK and Martin SVATON. Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, vol. 41, No 5, p. 2597-2603. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15039.

@article{1803921,
   author = {Krejci, Daniel and Opalka, Petr and Krejci, Jana and Zemanova, Milada and Zemanova, Petra and Kultan, Juraj and Fischer, Ondrej and Skřičková, Jana and Bratová, Monika and Cernovska, Marketa and Hrnciarik, Michal and Čoupková, Helena and Hurdálková, Karolína and Bařinová, Magda and Koubkova, Leona and Dolezal, Daniel and Safanda, Martin and Pesek, Milos and Svaton, Martin},
   article_location = {Athens},
   article_number = {5},
   doi = {http://dx.doi.org/10.21873/anticanres.15039},
   keywords = {NSCLC; chemotherapy; real-world data; bevacizumab; pemetrexed},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment},
   url = {https://ar.iiarjournals.org/content/41/5/2597},
   volume = {41},
   year = {2021}
}

TY  - JOUR
ID  - 1803921
AU  - Krejci, Daniel - Opalka, Petr - Krejci, Jana - Zemanova, Milada - Zemanova, Petra - Kultan, Juraj - Fischer, Ondrej - Skřičková, Jana - Bratová, Monika - Cernovska, Marketa - Hrnciarik, Michal - Čoupková, Helena - Hurdálková, Karolína - Bařinová, Magda - Koubkova, Leona - Dolezal, Daniel - Safanda, Martin - Pesek, Milos - Svaton, Martin
PY  - 2021
TI  - Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
JF  - Anticancer Research
VL  - 41
IS  - 5
SP  - 2597-2603
EP  - 2597-2603
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - NSCLC
KW  - chemotherapy
KW  - real-world data
KW  - bevacizumab
KW  - pemetrexed
UR  - https://ar.iiarjournals.org/content/41/5/2597
N2  - Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non small cell lung cancer (NSCLC) treatment. We conducted a real world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/ pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/ pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.
ER  -

KREJCI, Daniel, Petr OPALKA, Jana KREJCI, Milada ZEMANOVA, Petra ZEMANOVA, Juraj KULTAN, Ondrej FISCHER, Jana SKŘIČKOVÁ, Monika BRATOVÁ, Marketa CERNOVSKA, Michal HRNCIARIK, Helena ČOUPKOVÁ, Karolína HURDÁLKOVÁ, Magda BAŘINOVÁ, Leona KOUBKOVA, Daniel DOLEZAL, Martin SAFANDA, Milos PESEK and Martin SVATON. Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, vol.~41, No~5, p.~2597-2603. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15039.

Detailed Information on Publication Record